ABBV vs DIS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Walt Disney Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
AbbVie Inc. · Healthcare
$197.69
+11.0% upside to fair value
Grade C
High Quality
VS
The Walt Disney Company · Communication Services
$101.31
+66.6% upside to fair value
Grade B
QuantHub Verdict
DIS has more upside to fair value
(+66.6%).
DIS trades at a lower forward P/E
(14.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DIS |
| Current Price |
$197.69 |
$101.31 |
| Fair Value Estimate |
$219.51 |
$168.80 |
| Upside to Fair Value |
+11.0%
|
+66.6%
|
| Market Cap |
$349.7B |
$179.5B |
| Forward P/E |
83.3x
|
14.8x
|
| EV / EBITDA |
23.4x
|
11.4x
|
| Price / Sales |
5.7x
|
1.9x
|
| Price / FCF |
18.7x
|
25.4x
|
| Revenue Growth YoY |
+10.0%
|
+5.2%
|
| Gross Margin |
70.2%
|
37.3%
|
| Operating Margin |
26.7%
|
14.2%
|
| Return on Equity |
-361.6%
|
11.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.93%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
The Walt Disney Company operates as a diversified entertainment giant with strong competitive advantages from its vast intellectual property portfolio, global theme parks, and growing direct-to-consumer streaming platforms. The company demonstrates medium business quality with a durable moat supported by iconic brands and infrastructure, but faces execution risks in streaming profitability and pa…
Accumulation Zones
| Metric |
ABBV |
DIS |
| Zone Low |
$164.63 |
$126.60 |
| Zone High |
$186.58 |
$143.48 |
| In Buy Zone? |
No
|
Yes
|